Savara (NASDAQ:SVRA) Shares Down 3.4% – Time to Sell?

Savara Inc (NASDAQ:SVRA) shares were down 3.4% during trading on Wednesday . The stock traded as low as $3.63 and last traded at $3.65. Approximately 275,688 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 1,204,978 shares. The stock had previously closed at $3.78.

Wall Street Analyst Weigh In

Several analysts have recently commented on SVRA shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Savara in a report on Tuesday. Oppenheimer raised their price target on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. Guggenheim raised their price target on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $11.17.

Savara Stock Up 4.7 %

The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The firm has a 50-day simple moving average of $4.22 and a two-hundred day simple moving average of $4.40. The company has a market cap of $620.54 million, a PE ratio of -8.98 and a beta of 0.96.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Research analysts anticipate that Savara Inc will post -0.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bain Capital Life Sciences Investors LLC grew its position in shares of Savara by 2.3% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after purchasing an additional 332,706 shares during the period. Jennison Associates LLC boosted its holdings in Savara by 0.3% in the first quarter. Jennison Associates LLC now owns 8,841,971 shares of the company’s stock valued at $44,033,000 after acquiring an additional 26,613 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in Savara by 103.9% in the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after acquiring an additional 4,157,385 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Savara by 2.5% in the first quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after acquiring an additional 148,673 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its holdings in Savara by 198.2% in the second quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.